PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma.

Abstract

PANVAC is a cancer vaccine therapy delivered through two viral vectors--recombinant vaccinia and recombinant fowlpox--which are given sequentially. Both vectors contain transgenes for the tumor-associated antigens epithelial mucin 1 and carcinoembryonic antigen, which are altered or overexpressed in most carcinomas. The vectors also contain transgenes for three human T cell costimulatory molecules required to enhance immune response: B7.1, intracellular adhesion molecule-1 and leukocyte function-associated antigen-3. PANVAC is injected subcutaneously and processed by the body's antigen-presenting cells. Preclinical studies have demonstrated the efficacy of PANVAC in inducing both carcinoembryonic antigen- and mucin 1-specific cytotoxic T lymphocyte responses in vitro and in murine models. Other strategies that enhance the immune response include the use of granulocyte-macrophage colony-stimulating factor and a prime-boost administration sequence. Clinical trials have demonstrated PANVAC's safety and its ability to induce antigen-specific T cell responses. Early clinical trials are evaluating PANVAC alone and in combination with conventional chemotherapy and/or radiation. Studies to date hold promise for the use of PANVAC as a means to stimulate the immune system against malignancies and to provide clinical benefit.

• Authors: Ravi A Madan, Philip M Arlen, James L Gulley
• Journal: Expert opinion on biological therapy (Expert Opin Biol Ther) Vol. 7 Issue 4 Pg. 543-54 (Apr 2007) ISSN: 1744-7682 [Electronic] England
• PMID: 17373905 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Review)

Chemical References

• Cancer Vaccines
• Carcinoembryonic Antigen
• Membrane Glycoproteins
• Mucin-1
• Panvac-VF

Topics

• Cancer Vaccines (immunology, pharmacology, therapeutic use)
• Carcinoembryonic Antigen (drug effects, immunology, metabolism)
• Carcinoma (drug therapy, immunology, metabolism)
• Clinical Trials as Topic
• Humans
• Membrane Glycoproteins (immunology, pharmacology, therapeutic use)
• Mucin-1 (drug effects, immunology, metabolism)
• Treatment Outcome